RPRX CFO Terrance P. Coyne reports 10b5-1 share sales

Rhea-AI Filing Summary

Royalty Pharma plc (RPRX) EVP & CFO Terrance P. Coyne reported insider stock sales in a Form 4 filing. On 11/24/2025, multiple sales of Class A ordinary shares were executed, including 55,146 shares held indirectly through TPC RP 2021, LLC at a weighted average price of $38.6663 per share and 10,686 shares at a weighted average price of $37.9604 per share. Additional smaller sales were reported through TPC RP EPA1 LLC.

After these transactions, Coyne continues to hold significant indirect stakes, including 669,010 Class A ordinary shares via TPC RP 2021, LLC and 51,634 Class A ordinary shares via TPC RP EPA1 LLC, plus various IRA and spousal accounts. The filing also notes limited partnership interests exchangeable into 6,448,180 Class A ordinary shares and 1,807,277 Class E ordinary shares of Royalty Pharma Holdings Ltd, some of which are subject to vesting conditions. All reported sales were made under a Rule 10b5-1 trading plan adopted on August 8, 2025.

Insider Trade Summary

Net Seller: 69,582 shares ($2,682,505)

Net Sell 8 txns

Insider Coyne Terrance P.

Role EVP & CFO

Sold 69,582 shs ($2.68M)

Type	Security	Shares	Price	Value
Sale	Class A Ordinary Shares	55,146	$38.6663	$2.13M
Sale	Class A Ordinary Shares	10,686	$37.9604	$406K
Sale	Class A Ordinary Shares	3,126	$38.6699	$121K
Sale	Class A Ordinary Shares	624	$37.9595	$24K
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--

Holdings After Transaction: Class A Ordinary Shares — 669,010 shares (Indirect, By TPC RP 2021, LLC); Class A Ordinary Shares — 1,500 shares (Direct)

Footnotes (1)

1. All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.33 to $38.96 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.32 to $38.31 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coyne Terrance P.

(Last) (First) (Middle)

C/O ROYALTY PHARMA PLC

110 EAST 59TH STREET

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & CFO

3. Date of Earliest Transaction (Month/Day/Year)
11/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Shares	11/24/2025		S(1)		55,146	D	$38.6663(2)	669,010	I	By TPC RP 2021, LLC
Class A Ordinary Shares	11/24/2025		S(1)		10,686	D	$37.9604(3)	658,324	I	By TPC RP 2021, LLC
Class A Ordinary Shares	11/24/2025		S(1)		3,126	D	$38.6699(2)	51,634	I	TPC RP EPA1 LLC
Class A Ordinary Shares	11/24/2025		S(1)		624	D	$37.9595(3)	51,010	I	TPC RP EPA1 LLC
Class A Ordinary Shares								24,170	I	By Spouse's IRA
Class A Ordinary Shares								23,270	I	By IRA
Class A Ordinary Shares								1,500	D
Class A Ordinary Shares								1,450	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.33 to $38.96 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.32 to $38.31 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

In addition to the holdings of Class A Ordinary Shares disclosed above, the Reporting Person and family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP that are exchangeable into 6,448,180 Class A Ordinary Shares. The Reporting Person also holds 1,807,277 Class E Ordinary Shares of Royalty Pharma Holdings Ltd, certain of which are subject to vesting conditions and may, upon vesting, be converted into an equivalent number of Class A Ordinary Share.

	/s/ Sean Weisberg, as Attorney-in-Fact for Terrance P. Coyne	11/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Royalty Pharma (RPRX) disclose in this Form 4 filing?

The Form 4 reports that EVP & CFO Terrance P. Coyne executed multiple sales of Class A ordinary shares of Royalty Pharma plc (RPRX) on 11/24/2025, primarily through entities and accounts he indirectly controls.

How many Royalty Pharma (RPRX) shares did the CFO sell on 11/24/2025?

The transactions include sales such as 55,146 Class A ordinary shares at a weighted average price of $38.6663 per share and 10,686 shares at a weighted average price of $37.9604 per share, along with additional smaller sales reported in the table.

Were the Royalty Pharma (RPRX) insider sales made under a Rule 10b5-1 plan?

Yes. The filing states that all reported transactions were effected under a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025.

What Royalty Pharma (RPRX) holdings does the CFO report after these transactions?

Following the reported trades, the CFO reports indirect holdings including 669,010 Class A ordinary shares via TPC RP 2021, LLC, 51,634 shares via TPC RP EPA1 LLC, and additional amounts via a spouse's IRA, a personal IRA, and other direct and spousal accounts.

What additional Royalty Pharma-related interests does the CFO hold beyond the Class A shares?

The remarks disclose limited partnership interests in RPI US Partners 2019, LP that are exchangeable into 6,448,180 Class A ordinary shares, and 1,807,277 Class E ordinary shares of Royalty Pharma Holdings Ltd, some of which may convert into Class A ordinary shares upon vesting.

What price ranges applied to the reported Royalty Pharma (RPRX) share sales?

The filing explains that the weighted average prices reflect multiple trades. One set of sales occurred in a range from $38.33 to $38.96 per share, and another in a range from $37.32 to $38.31 per share.